We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




DNA-Based Vaccine Shown Safe and Effective

By LabMedica International staff writers
Posted on 16 Oct 2017
Print article
Image: A digitally colorized transmission electron micrograph (TEM) of Zika (Photo courtesy of the CDC).
Image: A digitally colorized transmission electron micrograph (TEM) of Zika (Photo courtesy of the CDC).
A team of vaccine developers used an advanced electroporation method to deliver and evaluate a new generation DNA-based vaccine designed to protect against Zika virus (ZIKV) infection.

Investigators at the University of Pennsylvania (Philadelphia, USA), Inovio Pharmaceuticals (Plymouth Meeting, PA, USA), GeneOne Life Science (Seoul, Korea), and The Wistar Institute (Philadelphia, PA, USA) collaborated in this effort. They used Inovio's proprietary electroporation device, Cellectra, to vaccinate two groups of 20 participants with two different doses of GeneOne Life Science's GLS-5700 DNA-based vaccine candidate.

Electroporation uses controlled, millisecond electrical pulses to create temporary pores in the cell membrane and allow dramatic cellular uptake of a synthetic DNA immunotherapy previously injected into muscle or skin. The cellular machinery then uses the DNA’s instructions to produce one or more proteins associated with the targeted disease. These foreign protein(s), or antigen(s), mimic the presence of an actual pathogen and induce an immune response to provide future protection against the pathogen or eliminate cells infected with an infectious disease or cancer.

In the current study, the GLS-5700 DNA vaccine, which encodes the ZIKV pre-membrane and envelope proteins, was administered by electroporation to two groups of 20 participants each. The participants received either one milligram or two milligrams of vaccine at baseline, four weeks, and 12 weeks.

Results published in the October 4, 2017, online edition of the New England Journal of Medicine revealed that by two weeks after the final dose all study participants had developed Zika-specific antibodies and 80% had produced significant neutralizing antibodies against the virus. Furthermore, serum from the study participants was able to protect immunocompromised mice from developing the disease after infection with Zika virus, indicating that the vaccine-induced antibodies could prevent infection in vivo.

By the 14-week point, no serious adverse events had been reported, although local reactions at the vaccination site (e.g., injection-site pain, redness, swelling, and itching) occurred in approximately 50% of the participants.

"Synthetic DNA vaccines are an ideal approach for emerging infectious diseases like Zika," said contributing author Dr. David B. Weiner, executive vice president of The Wistar Institute. "This new generation of DNA vaccines can be designed and manufactured rapidly, they appear to be highly predictable for the generation of immunity in humans, have significant conceptual safety advantages, and they are more stable than most traditional vaccines, making them exceptionally practical to distribute during outbreaks, especially in regions where resources are limited and we need to be able to respond quickly to curb an emerging epidemic."

Related Links:
University of Pennsylvania
Inovio Pharmaceuticals
GeneOne Life Science
The Wistar Institute
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.